President Donald Trump has signed an executive order imposing tariffs of up to 100% on certain imported patented pharmaceuticals and their active ingredients. The move, announced on Thursday, is designed to pressure drugmakers to lower U.S. prices and shift production to domestic facilities.
Immediate Action & Core Facts
The tariffs will apply to companies that have not reached agreements with the administration to lower drug prices or establish U.S. manufacturing operations. The policy creates a tiered system:
- 100% tariff: Applied to companies without pricing deals or onshoring plans.
- 20% tariff: For companies with approved onshoring plans, rising to 100% by 2030.
- 0% tariff: For companies with both pricing deals and active U.S. production plans.
Large companies will face the 100% tariff in 120 days, while smaller firms have 180 days before the rate applies. The administration has already secured deals with 13 companies, including Eli Lilly, Pfizer, and Novo Nordisk, with 17 more in negotiations.
Deeper Dive & Context
Policy Rationale
The White House justifies the tariffs as a national security measure, citing U.S. reliance on foreign pharmaceutical production. A memo states that 53% of patented pharmaceuticals distributed in the U.S. are imported, while only 15% of active ingredients are made domestically. The administration argues this dependence threatens access to life-saving medications during supply chain disruptions.
Incentivizing Domestic Production
The policy aims to encourage drugmakers to build U.S. facilities, with tariff exemptions or reductions for companies that commit to onshoring. The administration has noted $400 billion in investment commitments from pharmaceutical firms, including Eli Lilly and Pfizer, which have announced major plant development projects.
Most Favored Nation Pricing
The tariffs are tied to Trump’s “Most Favored Nation” drug pricing program, which seeks to align U.S. prices with those paid in other countries. Companies that enter pricing agreements with the Department of Health and Human Services (HHS) may qualify for lower or zero tariffs.
Industry and Political Reactions
The policy has drawn mixed reactions. Supporters argue it will reduce drug prices and strengthen U.S. manufacturing, while critics warn it could disrupt supply chains and raise costs for consumers. Some pharmaceutical companies have already begun negotiating deals to avoid the highest tariffs.
Enforcement and Timeline
The tariffs will be enforced through monitoring, external audits, and potential higher duties for non-compliant firms. The policy excludes generic drugs and applies only through January 2029. The administration has emphasized that companies still have time to negotiate deals before the highest rates take effect.